Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
OMCL 
Omnicell Inc (OMCL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: OMCL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $47.33
1 Year Target Price $47.33
| 3 | Strong Buy |
| 1 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 37.17% | Avg. Invested days 39 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.86B USD | Price to earnings Ratio 94.17 | 1Y Target Price 47.33 |
Price to earnings Ratio 94.17 | 1Y Target Price 47.33 | ||
Volume (30-day avg) 8 | Beta 0.83 | 52 Weeks Range 22.66 - 47.82 | Updated Date 12/6/2025 |
52 Weeks Range 22.66 - 47.82 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 1.69% | Operating Margin (TTM) 2.65% |
Management Effectiveness
Return on Assets (TTM) 0.54% | Return on Equity (TTM) 1.63% |
Valuation
Trailing PE 94.17 | Forward PE 29.5 | Enterprise Value 1829938610 | Price to Sales(TTM) 1.58 |
Enterprise Value 1829938610 | Price to Sales(TTM) 1.58 | ||
Enterprise Value to Revenue 1.55 | Enterprise Value to EBITDA 17.56 | Shares Outstanding 44876522 | Shares Floating 43770764 |
Shares Outstanding 44876522 | Shares Floating 43770764 | ||
Percent Insiders 1.84 | Percent Institutions 103.25 |
Upturn AI SWOT
Omnicell Inc
Company Overview
History and Background
Omnicell Inc. was founded in 1992. Initially focused on medication dispensing automation, it has evolved to offer a broad portfolio of solutions for medication management and adherence across the healthcare continuum. Key milestones include the development of automated dispensing cabinets, the expansion into data analytics and patient engagement, and acquisitions of companies specializing in medication adherence and pharmacy workflow optimization.
Core Business Areas
- Medication Management Systems: Provides automated dispensing cabinets, central pharmacy automation, and IV automation solutions for hospitals and health systems.
- Medication Adherence: Offers solutions such as medication synchronization, adherence packaging, and patient engagement tools for retail pharmacies and long-term care facilities.
- Data Analytics and Intelligence: Provides data analytics and insights to help healthcare providers improve medication management, reduce costs, and enhance patient outcomes.
Leadership and Structure
The CEO of Omnicell Inc is Nhat Hantuco. The company has a typical corporate structure with functional departments such as finance, marketing, sales, research and development, and operations. They have a board of directors overseeing the company's strategy and performance.
Top Products and Market Share
Key Offerings
- Automated Dispensing Cabinets (ADCs): Automated dispensing cabinets are a core offering, used for secure medication storage and dispensing in hospitals. Omnicell competes with BD (Becton, Dickinson and Company) (BDX) and Swisslog Healthcare. Omnicell holds a significant, yet contested, market share in the ADC market. Specific revenue breakdown for ADCs is not publicly available, but it represents a substantial portion of their total revenue.
- Central Pharmacy Automation: Includes robotic dispensing systems and inventory management solutions for central pharmacies. Competitors include Capsa Healthcare and ARxIUM. Revenue from central pharmacy automation contributes significantly to Omnicell's overall revenue.
- EnlivenHealth: Medication Adherence offerings, including synchronization and patient engagement tools. Competitors include DrFirst and AdhereRx. EnlivenHealth contribute a portion to Omnicell's overall revenue.
Market Dynamics
Industry Overview
The healthcare technology industry is experiencing growth driven by increasing demand for automation, data analytics, and patient engagement solutions. Key trends include the shift towards value-based care, the aging population, and the rising cost of healthcare. There is also increasing regulatory focus on patient safety and medication accuracy.
Positioning
Omnicell Inc. is a leading provider of medication management solutions. Its competitive advantages include its broad product portfolio, its established customer base, and its focus on innovation. It aims to improve safety and efficiency in healthcare settings.
Total Addressable Market (TAM)
The total addressable market for medication management and adherence solutions is estimated to be over $20 billion globally. Omnicell is well-positioned to capture a significant portion of this market, leveraging its existing customer relationships and expanding into new market segments.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Established customer base
- Strong brand reputation
- Focus on innovation
- Extensive Service network
Weaknesses
- High debt levels
- Integration challenges with acquired companies
- Dependence on hospital capital spending
- Customer concentration
Opportunities
- Expanding into new markets (e.g., long-term care)
- Developing new solutions for medication adherence
- Leveraging data analytics to improve patient outcomes
- Strategic partnerships
- Government regulations and incentives
Threats
- Increased competition
- Economic downturn
- Technological obsolescence
- Cybersecurity threats
- Changes in healthcare regulations
Competitors and Market Share
Key Competitors
- BDX
- MTD
- CAH
- WAT
Competitive Landscape
Omnicell faces competition from large healthcare companies with established customer bases. Its advantages include its broad product portfolio and its focus on innovation. Its disadvantages include its smaller size and its dependence on hospital capital spending.
Major Acquisitions
EnlivenHealth
- Year: 2021
- Acquisition Price (USD millions): 291
- Strategic Rationale: Expansion into medication adherence solutions and patient engagement. Strengthens retail pharmacy offerings.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by acquisitions and organic growth in medication management systems.
Future Projections: Analyst projections suggest continued growth in revenue, driven by demand for medication management solutions and expansion into new markets. However, profitability may be impacted by increased competition and rising operating costs.
Recent Initiatives: Recent initiatives include expanding into new markets, developing new solutions for medication adherence, and leveraging data analytics to improve patient outcomes.
Summary
Omnicell is a key player in medication management but faces increasing competition and integration hurdles post-acquisition. Its diverse product portfolio and focus on automation are strengths. However, its high debt and dependency on hospital spending present challenges. Strategic expansion and innovation are vital for sustained growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Omnicell Investor Relations
- SEC Filings (10K, 10Q)
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice. Market conditions and company performance may change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Omnicell Inc
Exchange NASDAQ | Headquaters Fort Worth, TX, United States | ||
IPO Launch date 2001-08-07 | Founder, Executive Chairman, President & CEO Mr. Randall A. Lipps | ||
Sector Healthcare | Industry Health Information Services | Full time employees 3600 | Website https://www.omnicell.com |
Full time employees 3600 | Website https://www.omnicell.com | ||
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care facilities. It also provides central pharmacy dispensing services; IV compounding services; turnkey solution designed to help health systems establish, manage, and optimize an entity-owned specialty pharmacy, as well as support onsite management of specialty pharmacy services, including payer contracting, staffing, licensing, and 340B program administration. In addition, the company offers inventory optimization services comprising predictive and prescriptive analytics, benchmarking, workflow tools, and clinical resources, as well as medication inventory visibility; patient engagement, clinical, and financial solutions; medication adherence solutions, which include single-dose automation solutions, automated and semi-automated filling equipment, various medication blister card packaging and packaging supplies; and software that guides users through the manual filling process. Further, it provides professional services, such as technology installation, program management, customer education and training, change management services, and related offerings; technical services comprising post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; and retail pharmacy and hospital automation outside the United States business. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. The company was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.